Clinical Trial Update: Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with cetuximab for recurrent/metastatic head and neck squamous cell carcinoma; the study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Lip Squamous Cell Carcinoma
• Nasopharyngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Sinonasal Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of California, San Diego | Conditions: HNSCC, Lip SCC | Phase 2 | Status: COMPLETED